telehealth glp-1 crackdown news FDA calls out Hims and other companies for advertising FDA moves to restrict compounded

503A patient-specific compounding by state-licensed pharmacies operates under a separate framework, though that framework also has restrictions when FDA-approved versions of a drug are available

All products are developed according to the same philosophy: genuine dry liposomes, produced in our own facility, without compromising on quality

With widely available FDA-approved medications, prescribers will transition patients from compounded versions

What to Expect During Treatment Tirzepatide is administered as a once-weekly subcutaneous injection

New information from current Phase III trials keeps improving the best ways to do things

Rulings given by the UKs Advertising Standards Authority (ASA) have made clear that advertising weight-loss drugs themselves is banned, as are claims and images indirectly advertising weight-loss drugs